RK
Robyn Karnauskas Truist Securities Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
AbCellera Biologics
ABCL
$1.26B
| $4.22 | $10 |
137%
upside
| Buy | 3 months ago |
|
2
Amgen
AMGN
$153B
| $283.64 | $298 |
5%
upside
| Hold | 8 months ago |
|
3
Bristol-Myers Squibb
BMY
$96B
| $47.14 | $65 |
38%
upside
| Buy | 8 months ago |
|
4
Merck
MRK
$212B
| $84.71 | $110 |
30%
upside
| Hold | 8 months ago |
|
5
Eli Lilly
LLY
$652B
| $727.21 | $1,029 |
42%
upside
| Buy | 10 months ago |
|
6
Gilead Sciences
GILD
$143B
| $115.05 | $83 |
28%
downside
| Hold | 1 year ago |
|
7
AbbVie
ABBV
$375B
| $212.56 | $210 |
1%
downside
| Buy | 1 year ago |
|
8
Biogen
BIIB
$20.6B
| $140.67 | $340 |
142%
upside
| Buy | 1 year ago |
|
9
Regeneron Pharmaceuticals
REGN
$60.8B
| $573.38 | $1,135 |
98%
upside
| Buy | 1 year ago |
|
10
Absci
ABSI
$368M
| $2.46 | $9 |
266%
upside
| Buy | 1 year ago |
|
11
Tourmaline Bio
TRML
$687M
| $26.74 | $74 |
177%
upside
| Buy | 1 year ago |
|
12
Roivant Sciences
ROIV
$8.82B
| $12.92 | $23 |
78%
upside
| Buy | 1 year ago |
|
13
Immunovant
IMVT
$2.99B
| $17.14 | $48 |
180%
upside
| Buy | 1 year ago |
|
14
Arcus Biosciences
RCUS
$1.3B
| $12.19 | $50 |
310%
upside
| Buy | 1 year ago |
|
15
Vertex Pharmaceuticals
VRTX
$102B
| $396.12 | $508 |
28%
upside
| Buy | 1 year ago |
|
16
Pfizer
PFE
$141B
| $24.88 | $36 |
45%
upside
| Buy | 1 year ago |
|
17
PTC Therapeutics
PTCT
$4.55B
| $57.26 | $25 |
56%
downside
| Hold | 1 year ago |
|
18
BioMarin Pharmaceuticals
BMRN
$11.1B
| $57.77 | $140 |
142%
upside
| Buy | 1 year ago |
|
19
uniQure
QURE
$985M
| $17.95 | $55 |
206%
upside
| Buy | 2 years ago |
|
20
Kodiak Sciences
KOD
$556M
| $10.52 | $15 |
43%
upside
| Buy | 3 years ago |
|
|
21
Arcus Biosciences
RCUS
$1.3B
| $12.19 | $53 |
335%
upside
| Buy | 3 years ago |
|
|
22
Amgen
AMGN
$153B
| $283.64 | $268 |
6%
downside
| Buy | 5 years ago |
|
|
23
Kodiak Sciences
KOD
$556M
| $10.52 | $89 |
746%
upside
| Buy | 5 years ago |
|
|
24
Regeneron Pharmaceuticals
REGN
$60.8B
| $573.38 | $750 |
31%
upside
| Buy | 5 years ago |
|
|
25
Vertex Pharmaceuticals
VRTX
$102B
| $396.12 | $325 |
18%
downside
| Buy | 5 years ago |
|